FREE Account Opening + No Clearing Fees
Loading...

Burger King IPO vs Gland Pharma IPO

Comparision between Burger King IPO and Gland Pharma IPO.

IPO Details

Burger King IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Gland Pharma IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Burger King IPO is up to ₹810.00 Cr whereas the issue size of the Gland Pharma IPO is up to ₹6,479.55 Cr. The final issue price of Burger King IPO is ₹60.00 per share and of Gland Pharma IPO is ₹1,500.00 per share.

  Burger King IPO Gland Pharma IPO
Face Value ₹10 per share ₹1 per share
Issue Price (Lower) ₹59.00 per share ₹1,490.00 per share
Issue Price (Upper) ₹60.00 per share ₹1,500.00 per share
Issue Price (Final) ₹60.00 per share ₹1,500.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 250 shares 10 shares
Fresh Issue Size 7,50,00,000 shares 83,33,333 shares
Fresh Issue Size (Amount) up to ₹450.00 Cr up to ₹1,250.00 Cr
OFS Issue Size 6,00,00,000 shares 3,48,63,635 shares
OFS Issue Size (Amount) up to ₹360.00 Cr up to ₹5,229.55 Cr
Issue Size Total 13,50,00,000 shares 4,31,96,968 shares
Issue Size Total (Amount) up to ₹810.00 Cr up to ₹6,479.55 Cr

IPO Timetable

Burger King IPO opens on Dec 02, 2020, while Gland Pharma IPO opens on Nov 09, 2020. The closing date of Burger King IPO and Gland Pharma IPO is Dec 04, 2020, and Nov 11, 2020, respectively.

  Burger King IPO Gland Pharma IPO
Anchor Bid Date
Issue Open Dec 02, 2020 Nov 09, 2020
Issue Close Dec 04, 2020 Nov 11, 2020
Basis Of Allotment (Tentative) Dec 09, 2020 Nov 17, 2020
Initiation of Refunds (Tentative) Dec 10, 2020 Nov 18, 2020
Credit of Share (Tentative) Dec 11, 2020 Nov 19, 2020
Listing date (Tentative) Dec 14, 2020 Nov 20, 2020
Anchor Lockin End date 1 Jan 08, 2021 Dec 17, 2020
Anchor Lockin End date 2 Mar 09, 2021 Feb 15, 2021

Financials

Burger King IPO P/E ratio is , as compared to Gland Pharma IPO P/E ratio of .

  Burger King IPO Gland Pharma IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in million)
30-Sep-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 11,771.18 11,977.07 9,204.72 7,303.55
Total Revenue 1,516.54 8,468.29 6,441.30 3,887.37
Profit After Tax (1,189.46) (765.70) (382.79) (822.32)
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in million)
30-June-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 46,912.65 40,860.39 35,235.49 29,294.68
Total Revenue 9,162.89 27,724.08 21,297.67 16,716.82
Profit After Tax 3,135.90 7,728.58 4,518.56 3,210.51
Promoter Shareholding (Pre-Issue) 99.39% 74%
Promoter Shareholding (Post-Issue) 60.08% 58%
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Burger King IPO retail investors (RII) are offered 1,36,27,118 shares while in Gland Pharma IPO retail investors are offered 1,36,27,118 shares. Qualified institutional buyers (QIB) are offered 4,04,23,729 shares in Burger King IPO and 86,39,394 shares in Gland Pharma IPO.

  Burger King IPO Gland Pharma IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 4,04,23,729 shares 86,39,394 shares
NII 2,04,40,677 shares 64,79,546 shares
RII 1,36,27,118 shares 1,51,18,939 shares
Employee 0 shares 0 shares
Others
Total 7,44,91,524 shares 3,02,37,879 shares

Bids Received (Subscription)

Burger King IPO subscribed 156.65x in total, whereas Gland Pharma IPO subscribed 2.06x.

  Burger King IPO Gland Pharma IPO
QIB (times) 86.64x 6.40x
NII (times) 354.11x 0.51x
Big NII (times)
Small NII (times)
RII (times) 68.15x 0.24x
Employee (times)
Other (times)
Total (times) 156.65x 2.06x

Comments

Add a public comment...